Developing Story
Linezolid – Antibiotic Repurposing for JAK2V617F Myeloproliferative Neoplasm
A preprint reports that linezolid, an FDA-approved antibiotic, may selectively inhibit JAK2V617F-harboring cells in polycythemia vera across multiple model systems. If confirmed, its existing regulatory status could accelerate repurposing timelines. The finding is pending peer review and clinical validation.
Importance: 72%Confidence: 65%Mentions: 1Updated: June 20, 2026
## Linezolid – Antibiotic Repurposing for JAK2V617F Myeloproliferative Neoplasm
### Overview
Researchers have reportedly discovered that linezolid (LZD), an FDA-approved antibiotic, may ameliorate the phenotype of polycythemia vera (PV) — a myeloproliferative neoplasm — by selectively inhibiting cells harboring the JAK2V617F (JAK2VF) driver mutation (biorxiv, 2026.05.31.729063v1). The finding is described as a potential breakthrough given current treatments' inability to eliminate mutant stem/progenitor cells.
### Background
- **JAK2V617F mutation**: Present in approximately 95% of PV patients; drives excessive hematopoiesis.
- **Current treatment limitations**: Existing therapies suppress symptoms but cannot selectively deplete JAK2VF-harboring cells and are subject to drug resistance.
- **Linezolid**: An oxazolidinone-class antibiotic approved for bacterial infections including MRSA; inhibits mitochondrial protein synthesis.
### Key Findings (Preprint)
- LZD reportedly suppressed cell proliferation and STAT5 signaling in JAK2VF-harboring human erythroleukemia cells.
- The compound altered the cell cycle and increased apoptosis specifically in JAK2VF cells across multiple model systems.
- Results were described as demonstrating selectivity for the mutant over wild-type cells, though peer review is pending.
### Strategic Relevance
- **Drug repurposing opportunity**: If confirmed, LZD's existing FDA approval may substantially reduce development timelines for a PV indication.
- **IP considerations**: Method-of-use patents on repurposed drugs are an active litigation area; first-mover filing around the JAK2VF-LZD mechanism may be commercially significant.
- **Competitive landscape**: Ruxolitinib (Jakafi) dominates the JAK inhibitor space for myeloproliferative neoplasms; a mechanism-differentiated therapy targeting mutant stem cells could command distinct market positioning.
- **Resistance risk**: Linezolid's mitochondrial mechanism is distinct from current JAK inhibitors, potentially offering a non-cross-resistant option.
### Status
Preprint only; peer review pending. Multiple model systems were tested, but clinical validation has not yet been reported.